RS Finn

1.0k total citations
40 papers, 793 citations indexed

About

RS Finn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, RS Finn has authored 40 papers receiving a total of 793 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in RS Finn's work include Advanced Breast Cancer Therapies (24 papers), HER2/EGFR in Cancer Research (14 papers) and Cancer Treatment and Pharmacology (12 papers). RS Finn is often cited by papers focused on Advanced Breast Cancer Therapies (24 papers), HER2/EGFR in Cancer Research (14 papers) and Cancer Treatment and Pharmacology (12 papers). RS Finn collaborates with scholars based in United States, Germany and France. RS Finn's co-authors include DJ Slamon, Éric Charpentier, Supriya Gupta, Anne Blackwood‐Chirchir, J. O’Shaughnessy, Eric P. Winer, Michael Danso, Denise A. Yardley, Lee S. Schwartzberg and H. S. Rugo and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

RS Finn

40 papers receiving 770 citations

Peers

Countries citing papers authored by RS Finn

Since Specialization

Citations

This map shows the geographic impact of RS Finn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by RS Finn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites RS Finn more than expected).

Fields of papers citing papers by RS Finn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by RS Finn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by RS Finn. The network helps show where RS Finn may publish in the future.

Co-authorship network of co-authors of RS Finn

This figure shows the co-authorship network connecting the top 25 collaborators of RS Finn. A scholar is included among the top collaborators of RS Finn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with RS Finn. RS Finn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma 2022 ·Annals of Oncology ·Shukui Qin, Masashi Kudo, T Meyer, RS Finn, Peter Vogel, Yibing Bai, (unknown), Zhefeng Meng, (unknown), Takeshi Satoh, (unknown), Donatella Marino, Éric Assenat, Lucjan Wyrwicz, (unknown), (unknown), (unknown), (unknown), (unknown), Andrew X. Zhu	54
2	169P Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis 2022 ·Annals of Oncology ·H. S. Rugo, Adam Brufsky, (unknown), (unknown), Lynn McRoy, C. Chen, (unknown), (unknown), (unknown), Giuseppe Curigliano, RS Finn, A. DeMichele	2
3	169P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC 2020 ·Annals of Oncology ·Masatoshi Kudo, Masafumi Ikeda, Andrew X. Zhu, (unknown), Tae‐Yop Kim, Ho Yeong Lim, В. В. Бредер, P. Merle, Ahmed S. Kaseb, (unknown), (unknown), (unknown), S Stanzel, Vincent E. Gaillard, (unknown), (unknown), Ann‐Lii Cheng, RS Finn, Peter R. Galle, Michel Ducreux	4
4	A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results 2019 ·Annals of Oncology ·Josep M. Llovet, (unknown), RS Finn, Masafumi Ikeda, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, H. Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, (unknown), Kalgi Mody, Tomoki Kubota, Kenichi Saito, (unknown), Leonid Dubrovsky, Andrew X. Zhu	52
5	Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240 2019 ·Annals of Oncology ·Philippe Merle, Amit S. Kulkarni, B-Y. Ryoo, Ann‐Lii Cheng, Masatoshi Kudo, Mohamed Bouattour, (unknown), В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, (unknown), Bruno Daniele, Josephine M. Norquist, (unknown), (unknown), Andrew X. Zhu, RS Finn	3
6	Evaluation of hepatocellular carcinoma circulating tumor cells expressing programmed death-ligand 1 2018 ·HPB ·Paul Winograd, Shuang Hou, Colin M. Court, Saeed Sadeghi, RS Finn, Benjamin J. DiPardo, (unknown), Fady M. Kaldas, Ronald W. Busuttil, James S. Tomlinson, Hsian‐Rong Tseng, Vatche G. Agopian	9
7	Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups 2018 ·Cancer Research ·HS Rugo, RS Finn, Véronique Dièras, Johannes Ettl, Oleg Lipatov, Anil A. Joy, Nadia Harbeck, Aurelio Castrellon, (unknown), A. Mori, (unknown), Cen Huang, (unknown), DJ Slamon	11
8	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH) 2018 ·Annals of Oncology ·Andrew X. Zhu, RS Finn, Peter R. Galle, Josep M. Llovet, (unknown), Takuji Okusaka, Ian Chau, Paolo Abada, Yanzhi Hsu, Masatoshi Kudo	13
9	Abstract P4-22-10: Evaluation of the effects of palbociclib (PAL) + letrozole (LET) on QTc 2017 ·Cancer Research ·(unknown), Eric Gauthier, Chandrasekar Durairaj, Xin Huang, Justin Hoffman, RS Finn, SL Moulder, (unknown), Johannes Ettl, HS Rugo, (unknown)	1
10	Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC) 2016 ·Annals of Oncology ·RS Finn, Yuqiu Jiang, Hope S. Rugo, SL Moulder, S.-A. Im, Karen A. Gelmon, Véronique Dièras, Miguel Martín, Anil A. Joy, Masakazu Toi, Eric Gauthier, Dongrui R. Lu, Cynthia Huang Bartlett, DJ Slamon	46
11	Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2 2016 ·Annals of Oncology ·Hope S. Rugo, Véronique Dièras, Karen A. Gelmon, RS Finn, DJ Slamon, Maria J. de Miguel, Patrick Neven, Johannes Ettl, Yaroslav Shparyk, A. Mori, Dongrui R. Lu, Helen Bhattacharyya, (unknown), Shrividya Iyer, Stephen Johnston, Nadia Harbeck	6
12	Clinical Patterns of Palbociclib Associated Neutropenia in the Paloma-1/Trio-18 Trial 2014 ·Annals of Oncology ·RS Finn, John Crown, Johannes Ettl, Tamás Pintér, (unknown), (unknown), Patrick Schnell, (unknown), Sophia Randolph, (unknown), Dennis J. Slamon	2
13	A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. 2011 ·Journal of Clinical Oncology ·RS Finn, Katalin Boér, (unknown), (unknown), Roshni Patel, (unknown), Christopher Hagenstad, Howard J. Lim, Tamás Pintér, D. Amadori, Ding‐Cheng Chan, Robert Dichmann, S. T. Kim, Sophia Randolph, DJ Slamon, John Crown	4
14	A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). 2011 ·Journal of Clinical Oncology ·J. O’Shaughnessy, Lee S. Schwartzberg, Michael Danso, H. S. Rugo, (unknown), Denise A. Yardley, (unknown), RS Finn, Éric Charpentier, (unknown), Supriya Gupta, Anne Blackwood‐Chirchir, Eric P. Winer	192
15	Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer. 2010 ·Journal of Clinical Oncology ·DJ Slamon, SA Hurvitz, Steven Applebaum, John A. Glaspy, (unknown), (unknown), Rachel Courtney, (unknown), Sophia Randolph, RS Finn	26
16	An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC) 2009 ·Journal of Clinical Oncology ·Jean‐Luc Raoul, RS Finn, Yoon‐Koo Kang, Ji Won Park, Rebecca Harris, (unknown), Margarita Donica, Ian Walters	50
17	Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents. 2009 ·Cancer Research ·RS Finn, Alexander Yuk Lun Lau, Ondrej Kalous, Douglas S. Conklin, Judy Dering, Charlotte Knights, Aisling O'Shaughnessy, Aaron Cranston, Lucy C. Riches, J. Carmichael, (unknown), DJ Slamon	5
18	Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008 2009 ·Journal of Clinical Oncology ·RS Finn, MF Press, Judy Dering, Allison Florance, (unknown), Michael Arbushites, María Koehler, S. Johnston	12
19	Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. 2009 ·Cancer Research ·RS Finn, Carmelo Bengala, (unknown), (unknown), Justin Fairchild, Oumar Sy, H. Roché, (unknown), LJ Goldstein	59
20	Correlation of HER2 gene amplification, HER2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer 2008 ·Journal of Clinical Oncology ·MF Press, RS Finn, Angelo Di Leo, David Cameron, Charles E. Geyer, Anne Marie Martin, B. Newstat, (unknown), Michael Arbushites, Martin Johannes Koehler	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact